PO.TB08.01 · 肿瘤生物学

SORL1通过调控integrin转运促进卵巢癌细胞的间皮清除和迁移

SORL1 promotes mesothelial clearance and migration of ovarian cancer cells through regulating integrin trafficking

海报缩略图:SORL1通过调控integrin转运促进卵巢癌细胞的间皮清除和迁移
编号 7486 展板 4 时间 4/22 09:00–12:00 区域 Section 30 主讲 Jasmine Jathan, BS;MS
分会场 Tumor Adhesion
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Jasmine Jathan, Viktoriia Kolesnyk, Samantha Goncalves Novo, Miranda Mansolf, Yang Yang-Hartwich

Yale School of Medicine, New Haven, CT

摘要 Abstract

中文摘要
背景:腹膜播散是晚期卵巢癌的一个标志,也是患者预后不良的主要原因。卵巢癌转移涉及黏附、侵袭以及细胞-基质相互作用的动态重塑,其中integrin转运发挥核心作用。胞内分选受体SORL1调控受体再循环和胞内转运,有证据将其活性与多种癌症中的致癌信号相联系。基于我们先前发现SORL1调控卵巢癌中EGFR1和FGFR4的内体转运和再循环,本研究旨在探讨SORL1如何通过调节integrin转运和内体再循环来调控卵巢癌的侵袭和转移。同时评估了在复发性卵巢癌中通过靶向SORL1抑制肿瘤腹膜播散和转移的治疗潜力。 方法:使用siRNA/shRNA在患者来源的卵巢癌细胞中敲低SORL1表达。将肿瘤球体与间皮细胞共培养以量化癌细胞清除效率。通过与内体标志物免疫荧光共染色和共聚焦显微镜成像检测integrin定位。流式细胞术在有或无纤连蛋白(作为细胞外基质配体)激活的情况下测量细胞表面integrin水平。共免疫沉淀和邻近测定评估SORL1依赖性的integrin alpha3/beta1与转运接头GGA1之间的相互作用。最后,评估了一种SORL1阻断蛋白对抑制卵巢癌迁移和间皮清除的活性。 结果:SORL1敲低显著降低了卵巢癌侵袭和间皮清除。免疫荧光染色分析显示SORL1抑制后integrin-a3的内化增强,表现出从质膜向胞内内体区室的转移。与之一致,SORL1敲低细胞在纤连蛋白激活后表面integrin水平降低,表明integrin再循环受损。SORL1敲低细胞中integrin与GGA1相互作用增加,提示其在早期内体和再循环内体中积累。SORL1阻断抗体抑制了卵巢癌迁移和间皮清除。这些发现表明,SORL1的缺失破坏了integrin转运和表面表达,从而损害卵巢癌中integrin介导的黏附和侵袭。 结论:SORL1调控integrin转运和再循环,以维持卵巢癌细胞中integrin介导的黏附和侵袭。SORL1的缺失破坏了这些过程,限制腹膜播散。靶向SORL1依赖性转运通路可能为抑制卵巢癌转移提供治疗潜力。
查看英文原文 English abstract
Background: Peritoneal dissemination is a hallmark of advanced ovarian cancer and leading cause of poor patient prognosis. Ovarian cancer metastasis involves adhesion, invasion, and dynamic remodeling of cell-matrix interactions, where integrin trafficking plays a central role. The intracellular sorting receptor, SORL1 regulates receptor recycling and intracellular trafficking, with evidence linking its activity to oncogenic signaling in various cancers. Building on our prior findings that SORL1 modulates endosomal trafficking and recycling of EGFR1 and FGFR4 in ovarian cancer, this study aimed to investigate how SORL1 regulates ovarian cancer invasion and metastasis by modulating integrin trafficking and endosomal recycling. The therapeutic potential of inhibiting tumor peritoneal dissemination and metastasis in recurrent ovarian cancer by targeting SORL1 was also evaluated. Methods: SORL1 expression was knocked down in patient‑derived ovarian cancer cells using siRNA/shRNA. Tumor spheroid co‑cultured with mesothelial cells were used to quantify cancer cell clearance efficiency. Integrin localization was examined by immunofluorescence co‑staining with endosomal markers and confocal microscope imaging. Flow cytometry measured cell surface integrin levels with and without activation by fibronectin as an extracellular matrix ligand. Co‑immunoprecipitation and proximity assays assessed SORL1-dependent interactions between integrins alpha3/beta1 and the trafficking adaptor GGA1. Finally, the activity of a SORL1-blocking protein on inhibition of ovarian cancer migration and mesothelial clearance was evaluated. Results: SORL1 knockdown significantly reduced ovarian cancer invasion and mesothelial clearance. Immunofluorescence staining analysis revealed enhanced internalization of integrin-a3 upon SORL1 inhibition, showing a shift from the plasma membrane to intracellular endosomal compartments. Consistently, the decreased surface levels of integrins after fibronectin activation in SORL1‑knockdown cells indicated impaired integrin recycling. Increased interaction of integrins with GGA1 in SORL1 knockdown cells suggested accumulation in early and recycling endosomes. SORL1-blocking antibody inhibited ovarian cancer migration and mesothelial clearance. These findings demonstrate that loss of SORL1 disrupts integrin trafficking and surface expression, thereby impairing integrin‑mediated adhesion and invasion in ovarian cancer. Conclusion: SORL1 regulates integrin trafficking and recycling to maintain integrin‑mediated adhesion and invasion in ovarian cancer cells. Loss of SORL1 disrupts these processes, limiting peritoneal dissemination. Targeting SORL1‑dependent trafficking pathways may offer therapeutic potential to inhibit ovarian cancer metastasis.
利益披露 Disclosure
J. Jathan, None.. V. Kolesnyk, None.. S. G. Novo, None.. M. Mansolf, None.

← 返回 AACR 2026 检索